FOURTH WAIVER TO AGREEMENT AND PLAN OF MERGER
Exhibit 99.1
This FOURTH WAIVER TO AGREEMENT AND PLAN OF MERGER (this “Waiver”), dated October 18, 2024, is made by and among Crown Laboratories,
Inc., a Delaware corporation (“Parent”), Xxxx Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”), and Revance Therapeutics, Inc., a Delaware corporation (the ”Company”), and waives certain provisions (as
set forth herein) of that certain Agreement and Plan of Merger, dated August 11, 2024 (as the same may be amended, modified or restated in accordance with the terms thereof, the “Merger Agreement”), by and among Parent, Merger Sub and the Company.
Capitalized terms used herein but not otherwise defined shall have the meanings ascribed to them in the Merger Agreement.
WHEREAS, pursuant to that certain Waiver to the Agreement and Plan of Merger, dated as of August 27, 2024 (the “First Waiver”), the
parties hereto have previously agreed to extend the time under Section 2.1(a) of the Merger Agreement by which the Offer is to be commenced pursuant to the Merger Agreement;
WHEREAS, pursuant to that certain Second Waiver to the Agreement and Plan of Merger, dated as of September 19, 2024 (the “Second
Waiver”), the parties hereto have previously agreed to further extend the time under Section 2.1(a) of the Merger Agreement by which the Offer is to be commenced pursuant to the Merger Agreement;
WHEREAS, pursuant to that certain Third Waiver to the Agreement and Plan of Merger, dated as of October 3, 2024 (the “Third Waiver”),
the parties hereto have previously agreed to further extend the time under Section 2.1(a) of the Merger Agreement by which the Offer is to be commenced pursuant to the Merger Agreement; and
WHEREAS, the parties hereto have agreed to further extend the time under Section 2.1(a) of the Merger Agreement by which the Offer is
to be commenced pursuant to the Merger Agreement as set forth herein.
NOW, THEREFORE, the parties hereto agree as follows:
1. Extension of Commencement of the Offer under Section 2.1(a) of the Merger Agreement.
The parties hereto acknowledge and agree, notwithstanding the First Waiver, Second Waiver and Third Waiver, that the reference in the first parenthetical in the first sentence of Section 2.1(a) of the Merger Agreement that the Offer be commenced
thereunder within 15 Business Days after the date of the Merger Agreement is hereby extended to October 25, 2024 or such other date as may be agreed to between the Company and Parent.
2. Counterparts; Effectiveness. Except as otherwise expressly provided herein, the
terms, provisions and conditions of the Merger Agreement shall remain unchanged and the Merger Agreement shall be construed in a manner consistent with this Waiver. This Waiver may be executed in any number of counterparts and by different
parties hereto in separate counterparts, each of which when so executed and delivered shall be deemed an original, but all such counterparts together shall constitute but one and the same instrument.
IN WITNESS WHEREOF, the parties have caused this Waiver to be executed and delivered by their respective duly authorized officers as
of the date first written above.
|
CROWN LABORATORIES, INC.
|
|||
|
By:
|
/s/ Xxxxxxx X. Xxxxxx
|
||
|
Name:
|
Xxxxxxx X. Xxxxxx
|
||
|
Title:
|
Chief Executive Officer
|
||
|
XXXX MERGER SUB, INC.
|
|||
|
By:
|
/s/ Xxxxxxx X. Xxxxxx
|
||
|
Name:
|
Xxxxxxx X. Xxxxxx
|
||
|
Title:
|
Chief Executive Officer
|
||
|
By:
|
/s/ Xxxx X. Xxxxx
|
||
|
Name:
|
Xxxx Xxxxx
|
||
|
Title:
|
President and Chief Executive Officer
|
||
